Skip to Main Content
DownloadHi-Res Photo

Christina Price, MD

Assistant Professor of Medicine (Immunology) and of Pediatrics (Immunology); Clinical Chief of Allergy and Immunology, Rheumatology, Allergy, & Immunology; VA Medical Center Section Chief, Allergy and Clinical Immunology

Contact Information

Christina Price, MD

Mailing Address

  • Allergy & Clinical Immunology

    PO Box 208013

    New Haven, CT 06520-8013

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

immune deficiency in autoimmunity

immunotoxicity in patients receiving checkpoint inhibitor

Coauthors

Selected Publications

  • Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group., Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021.
  • Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose.Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.
  • Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.
  • Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support.Kaman K, Azmy V, Chichra A, Britto-Leon C, Price C. Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support. Respiratory Medicine Case Reports 2021, 33: 101376. PMID: 33680800, PMCID: PMC7925237, DOI: 10.1016/j.rmcr.2021.101376.
  • Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
  • Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opinion On Investigational Drugs 2020, 29: 1407-1412. PMID: 33094669, DOI: 10.1080/13543784.2020.1840549.
  • Optimizing Care for Patients With Adverse Events From Immunotherapeutics.Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer Journal (Sudbury, Mass.) 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/PPO.0000000000000492.
  • Subtle But Clinically Significant: A Review of Antibody Deficiency in AdultsHarada K, Price C. Subtle But Clinically Significant: A Review of Antibody Deficiency in Adults, Clin Pulm Med. 26(3):71-75 May 2019
  • Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. The Journal Of Allergy And Clinical Immunology 2018, 142: 1932-1946. PMID: 29729943, PMCID: PMC6215742, DOI: 10.1016/j.jaci.2018.02.055.
  • Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long? The Journal Of Allergy And Clinical Immunology 2015, 136: 1407-9. PMID: 26277594, DOI: 10.1016/j.jaci.2015.06.035.
  • Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era.Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, Won CH, Chun HJ. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. The Lancet. Microbe 2021 PMID: 34901896, PMCID: PMC8641954, DOI: 10.1016/S2666-5247(21)00306-2.
Edit Profile